← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Astrocyte Pharmaceuticals, Inc.
Cambridge, MA
$5,465,311
Total funding
4
Grants
Funding over time
peak $1.7M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,465,311 · 4
By mechanism
R44$4,495,704 · 2
R41$969,607 · 2
Investigators at Astrocyte Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Preclinical Efficacy and Safety Evaluation of Oral AST-004 for Moderate Traumatic Brain Injury (TBI)$1,499,886
R44 · FY2025 · NS
Preclinical development of AST-004 for astrocyte-mediated treatment of TBI.$1,499,342
R44 · FY2019 · NS
Preclinical development of AST-004 for astrocyte-mediated treatment of TBI.$1,496,476
R44 · FY2018 · NS
ASTROCYTE ACTIVATION BY SMALL MOLECULE P2Y1 AGONISTS FOR TREATMENT OF TBI$420,239
R41 · FY2015 · NS
ASTROCYTE ACTIVATION BY SMALL MOLECULE P2Y1 AGONISTS FOR TREATMENT OF TBI$251,420
R41 · FY2016 · NS
Astrocyte activation by small-molecule ADORA3 agonists: a novel therapy for Alzheimer's disease$199,830
R41 · FY2018 · AG
Astrocyte activation by small-molecule ADORA3 agonists: a novel therapy for Alzheimer's disease$98,118
R41 · FY2019 · AG